Iovance TIL therapy hits 59% ORR in biomarker-enriched NSCLC cohort

Iovance's lifileucel achieved a 59% response rate in a KRAS/HER2 wild-type mNSCLC subgroup, prompting a new precision TIL trial with registrational intent.

A clear IV drip bag hangs from a metallic pole in a brightly lit medical room with multiple recliners and large windows.

Iovance Biotherapeutics has reported updated Phase 2 data for its TIL cell therapy lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer, and announced a new biomarker-enriched trial designed with a path to regulatory approval.

In the broader IOV-LUN-202 Cohorts 1 and 2, 17 of 69 evaluable patients responded to lifileucel, yielding an objective response rate (ORR) of 24.6% as of an October 2026 data cut. That figure is broadly consistent with the 25.6% ORR reported when the cohort comprised 39 patients, suggesting the signal has held as enrolment progressed. The full dataset is expected to reach approximately 80 patients, and Iovance said it intends to file a supplemental Biologics Licence Application (sBLA) with the FDA for lifileucel in non-squamous mNSCLC in 2027. Discussions with the FDA are ongoing.

Precision signal drives strategy shift

The more striking finding is the response distribution across molecular subgroups. A retrospective analysis showed that patients with KRAS wild-type tumours achieved a 43.3% ORR, compared with 11.4% in patients with KRAS-mutant disease. Iovance then refined the enrichment criteria further, adding HER2 wild-type status and current or former smoking history. The 22 patients meeting all three criteria, roughly a third of the broader cohort, achieved a 59.1% ORR and accounted for more than three-quarters of all responses, including both complete responses observed in the trial.

The biological rationale draws on published preclinical work linking oncogenic KRAS signalling to impaired tumour antigen presentation and immune suppression, and on evidence that aberrant HER2 signalling can dampen antitumour immunity. Smoking-associated mutational burden, meanwhile, is thought to generate more tumour targets accessible to polyclonal TIL. Together, these criteria are designed to select patients whose tumour biology is conducive to a sustained TIL response.

Frederick Vogt, interim president and chief executive of Iovance, said: "In the enriched subgroup, nearly six in ten patients responded, including two complete responses. We believe these insights could expand lifileucel's potential as a one-time treatment for mNSCLC."

Iovance has now launched POSITILITY, a prospective, biomarker-enriched cohort within the IOV-LUN-202 programme, with enrolment to begin in November 2026 across more than 70 existing study sites. A separate frontline trial, OPTIMISM, is planned for 2027. Supporting that ambition, a small exploratory cohort from the IOV-COM-202 study showed six of seven KRAS wild-type, ever-smoker patients responded to lifileucel combined with pembrolizumab in the first-line setting, an 85.7% ORR, though the numbers are too small to draw firm conclusions.

Market context and competitive landscape

The move toward a precision TIL strategy reflects a broader maturation of the cell therapy field. TIL approaches have historically been applied without molecular pre-selection, which has limited their competitiveness against approved checkpoint inhibitors and antibody-drug conjugates in solid tumours. By stratifying patients using standard genomic testing and routinely collected smoking history, Iovance is attempting to close that gap without requiring a bespoke companion diagnostic from scratch.

Lifileucel already holds FDA approval for previously treated advanced melanoma under the brand name Amtagvi, giving Iovance a commercial manufacturing infrastructure and a network of nearly 100 authorised treatment centres. That operational base is a meaningful differentiator in a field where manufacturing complexity remains a constraint for newer entrants. The company estimates the biomarker-enriched non-squamous mNSCLC population represents roughly 45% of annual US cases, equating to more than 90,000 deaths per year, though such market-sizing figures should be treated as indicative rather than precise.

Second-line mNSCLC remains an intensely contested indication. Iovance's ability to convert the POSITILITY trial into a registrational data package and navigate the sBLA process for the broader population simultaneously will be closely watched by investors ahead of anticipated updates in 2027.